{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T10:14:34Z","timestamp":1784196874310,"version":"3.55.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.jtha.2025.09.038","type":"journal-article","created":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T14:37:14Z","timestamp":1761316634000},"page":"155-160","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Concizumab use in toddlers with hemophilia B and inhibitors real-world data from an international collaboration"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3971-0336","authenticated-orcid":false,"given":"Sarina","family":"Levy-Mendelovich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Timmermans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Nolan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabina","family":"Heine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Achini-Gutzwiller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison P.","family":"Wheeler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gili","family":"Kenet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2025.09.038_bib1","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/S0140-6736(24)02139-1","article-title":"Haemophilia","volume":"405","author":"Chowdary","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.jtha.2025.09.038_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcmd.2019.102370","article-title":"Allergy and inhibitors in hemophilia\u2014a rare complication with potential novel solutions","volume":"80","author":"Levy-Mendelovich","year":"2020","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.jtha.2025.09.038_bib3","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3324\/haematol.2019.239160","article-title":"Inhibitor incidence in an unselected cohort of previously untreated patients with severe haemophilia B: a PedNet study","volume":"106","author":"Male","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.jtha.2025.09.038_bib4","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1111\/j.1365-2516.2007.01463.x","article-title":"Achievement of immune tolerance in a patient with haemophilia B and inhibitory antibodies, complicated by an anaphylactoid reaction","volume":"13","author":"Curry","year":"2007","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2025.09.038_bib5","first-page":"1253","article-title":"Concizumab: First approval. Drugs. 2023;83:1053\u22129","volume":"83","author":"Keam","year":"2023","journal-title":"Erratum in: Drugs"},{"key":"10.1016\/j.jtha.2025.09.038_bib6","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1182\/blood.2023021864","article-title":"Fitusiran prophylaxis in people with hemophilia A or B who switched from prior BPA\/CFC prophylaxis: the ATLAS-PPX trial","volume":"143","author":"Kenet","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.09.038_bib7","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s40265-024-02130-4","article-title":"Marstacimab: First approval","volume":"85","author":"Lamb","year":"2025","journal-title":"Drugs"},{"key":"10.1016\/j.jtha.2025.09.038_bib8","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJMoa2216455","article-title":"Phase 3 trial of concizumab in hemophilia with inhibitors","volume":"389","author":"Matsushita","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.09.038_bib9","series-title":"Procedures for Coagulation Laboratory","first-page":"69","article-title":"Physiologic and pathologic inhibitors","author":"Triplett","year":"1981"},{"key":"10.1016\/j.jtha.2025.09.038_bib10","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1111\/ijlh.13100","article-title":"Performance evaluation of a new Stago\u00ae automated haemostasis analyser: The STA R Max\u00ae 2","volume":"41","author":"Cupaiolo","year":"2019","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.jtha.2025.09.038_bib11","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/jth.12864","article-title":"Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial","volume":"13","author":"Chowdary","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.09.038_bib12","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1160\/TH06-07-0408","article-title":"Thrombin generation, a function test of the haemostatic-thrombotic system","volume":"96","author":"Hemker","year":"2006","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.09.038_bib14","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1055\/s-0037-1617018","article-title":"ITI with high-dose FIX and combined immunosuppressive therapy in a patient with severe haemophilia B and inhibitor","volume":"29","author":"Beutel","year":"2009","journal-title":"Hamostaseologie"},{"key":"10.1016\/j.jtha.2025.09.038_bib13","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1182\/blood.V89.3.1115","article-title":"Nephrotic syndrome as a complication of immune tolerance in hemophilia B","volume":"89","author":"Ewenstein","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.09.038_bib15","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.2147\/PPA.S470091","article-title":"The concizumab pen-injector is easy to use and preferred by hemophilia patients and caregivers: a usability study assessing pen-injector handling and preference","volume":"18","author":"Kahr Rasmussen","year":"2024","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.jtha.2025.09.038_bib16","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1111\/hae.14595","article-title":"Befovacimab, an anti-tissue factor pathway inhibitor antibody: early termination of the multiple-dose, dose-escalating Phase 2 study due to thrombosis","volume":"28","author":"Mancuso","year":"2022","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2025.09.038_bib17","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1046\/j.1365-2516.9.s1.7.x","article-title":"Central venous lines in haemophilia","volume":"9","author":"Ljung","year":"2003","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2025.09.038_bib18","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1111\/hae.14813","article-title":"Longitudinal observations of TFPI levels in paediatric haemophilia A patients","volume":"29","author":"Schwers","year":"2023","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2025.09.038_bib19","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1111\/jth.14272","article-title":"A randomized trial of safety, pharmacokinetics and pharmacodynamics of concizumab in people with hemophilia A","volume":"16","author":"Eichler","year":"2018","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.09.038_bib20","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/hae.13627","article-title":"Concizumab restores thrombin generation potential in patients with haemophilia: pharmacokinetic\/pharmacodynamic modelling results of concizumab phase 1\/1b data","volume":"25","author":"Eichler","year":"2019","journal-title":"Haemophilia"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783625006634?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783625006634?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T08:38:09Z","timestamp":1767602289000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783625006634"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S1538783625006634"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2025.09.038","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Concizumab use in toddlers with hemophilia B and inhibitors real-world data from an international collaboration","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2025.09.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}